Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma

Theodore F. Reiss, Leonard C. Altman, Paul Chervinsky, Againdra K. Bewtra, William E. Stricker, Gertrude P. Noonan, Sudeep Kundu, Ji Zhang

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Background: Cysteinyl leukotrienes mediate signs and symptoms of asthma. In a double-blind, placebo-controlled, crossover study, a new potent and specific cysteinyl leukotriene (LTD4) receptor antagonist, montelukast (MK-0476), was evaluated for tolerability and clinical efficacy in patients with chronic asthma (receiving and not receiving inhaled corticosteroids). Methods: Twenty-nine nonsmoking patients with asthma (15 treated concomitantly with inhaled corticosteroids) with FEV1 percent predicted values between 50% to 80% received MK-0476, 200 mg, or placebo three times daily for 101/3 days (31 doses) in a random, crossover manner, after a 2-week, open, baseline period. Comparisons in FEV1 (mean percent change from baseline after the first and last dose), mean daily daytime asthma and nocturnal awakening scores, and mean daily β-agonist use were made between treatment periods. Results: Montelukast, compared with placebo, caused improvements in FEV1 (mean percentage point difference of the percentage change from baseline) 3 and 4 hours after dosing on day 1 (hour 3, 9.0%; 95% confidence interval [CI] 0.53, 18.72; hour four, 10.9%; 95% CI - 0.25, 20.20) and day 11 (hour 3, 14.0%; 95% CI 0.76, 31.43; hour 4, 13.4%; 95% CI 1.24, 28.83). Reductions were observed in mean daily β-agonist use (1.0 puff/day [95% CI -1.61, -0.26]), mean daytime symptom scores, and nocturnal awakenings over the 101/3 day treatment period. There were no important differences between the groups receiving and those not receiving inhaled corticosteroids. Montelukast was well tolerated with no serious clinical adverse events reported. Conclusions: In this study Montelukast, 200 mg, administered three times daily for 101/3 days, compared with placebo, was generally well tolerated and resulted in significant improvement in chronic asthma, irrespective of the presence of inhaled corticosteroids.

Original languageEnglish
Pages (from-to)528-534
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume98
Issue number3
StatePublished - 1996

Fingerprint

montelukast
Leukotriene Antagonists
Asthma
Confidence Intervals
Adrenal Cortex Hormones
Placebos
Cross-Over Studies
Signs and Symptoms
leukotriene D4 receptor

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cite this

Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. / Reiss, Theodore F.; Altman, Leonard C.; Chervinsky, Paul; Bewtra, Againdra K.; Stricker, William E.; Noonan, Gertrude P.; Kundu, Sudeep; Zhang, Ji.

In: Journal of Allergy and Clinical Immunology, Vol. 98, No. 3, 1996, p. 528-534.

Research output: Contribution to journalArticle

Reiss, TF, Altman, LC, Chervinsky, P, Bewtra, AK, Stricker, WE, Noonan, GP, Kundu, S & Zhang, J 1996, 'Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma', Journal of Allergy and Clinical Immunology, vol. 98, no. 3, pp. 528-534.
Reiss, Theodore F. ; Altman, Leonard C. ; Chervinsky, Paul ; Bewtra, Againdra K. ; Stricker, William E. ; Noonan, Gertrude P. ; Kundu, Sudeep ; Zhang, Ji. / Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. In: Journal of Allergy and Clinical Immunology. 1996 ; Vol. 98, No. 3. pp. 528-534.
@article{622b44a9ae504b2c975b602194ca86ef,
title = "Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma",
abstract = "Background: Cysteinyl leukotrienes mediate signs and symptoms of asthma. In a double-blind, placebo-controlled, crossover study, a new potent and specific cysteinyl leukotriene (LTD4) receptor antagonist, montelukast (MK-0476), was evaluated for tolerability and clinical efficacy in patients with chronic asthma (receiving and not receiving inhaled corticosteroids). Methods: Twenty-nine nonsmoking patients with asthma (15 treated concomitantly with inhaled corticosteroids) with FEV1 percent predicted values between 50{\%} to 80{\%} received MK-0476, 200 mg, or placebo three times daily for 101/3 days (31 doses) in a random, crossover manner, after a 2-week, open, baseline period. Comparisons in FEV1 (mean percent change from baseline after the first and last dose), mean daily daytime asthma and nocturnal awakening scores, and mean daily β-agonist use were made between treatment periods. Results: Montelukast, compared with placebo, caused improvements in FEV1 (mean percentage point difference of the percentage change from baseline) 3 and 4 hours after dosing on day 1 (hour 3, 9.0{\%}; 95{\%} confidence interval [CI] 0.53, 18.72; hour four, 10.9{\%}; 95{\%} CI - 0.25, 20.20) and day 11 (hour 3, 14.0{\%}; 95{\%} CI 0.76, 31.43; hour 4, 13.4{\%}; 95{\%} CI 1.24, 28.83). Reductions were observed in mean daily β-agonist use (1.0 puff/day [95{\%} CI -1.61, -0.26]), mean daytime symptom scores, and nocturnal awakenings over the 101/3 day treatment period. There were no important differences between the groups receiving and those not receiving inhaled corticosteroids. Montelukast was well tolerated with no serious clinical adverse events reported. Conclusions: In this study Montelukast, 200 mg, administered three times daily for 101/3 days, compared with placebo, was generally well tolerated and resulted in significant improvement in chronic asthma, irrespective of the presence of inhaled corticosteroids.",
author = "Reiss, {Theodore F.} and Altman, {Leonard C.} and Paul Chervinsky and Bewtra, {Againdra K.} and Stricker, {William E.} and Noonan, {Gertrude P.} and Sudeep Kundu and Ji Zhang",
year = "1996",
language = "English",
volume = "98",
pages = "528--534",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma

AU - Reiss, Theodore F.

AU - Altman, Leonard C.

AU - Chervinsky, Paul

AU - Bewtra, Againdra K.

AU - Stricker, William E.

AU - Noonan, Gertrude P.

AU - Kundu, Sudeep

AU - Zhang, Ji

PY - 1996

Y1 - 1996

N2 - Background: Cysteinyl leukotrienes mediate signs and symptoms of asthma. In a double-blind, placebo-controlled, crossover study, a new potent and specific cysteinyl leukotriene (LTD4) receptor antagonist, montelukast (MK-0476), was evaluated for tolerability and clinical efficacy in patients with chronic asthma (receiving and not receiving inhaled corticosteroids). Methods: Twenty-nine nonsmoking patients with asthma (15 treated concomitantly with inhaled corticosteroids) with FEV1 percent predicted values between 50% to 80% received MK-0476, 200 mg, or placebo three times daily for 101/3 days (31 doses) in a random, crossover manner, after a 2-week, open, baseline period. Comparisons in FEV1 (mean percent change from baseline after the first and last dose), mean daily daytime asthma and nocturnal awakening scores, and mean daily β-agonist use were made between treatment periods. Results: Montelukast, compared with placebo, caused improvements in FEV1 (mean percentage point difference of the percentage change from baseline) 3 and 4 hours after dosing on day 1 (hour 3, 9.0%; 95% confidence interval [CI] 0.53, 18.72; hour four, 10.9%; 95% CI - 0.25, 20.20) and day 11 (hour 3, 14.0%; 95% CI 0.76, 31.43; hour 4, 13.4%; 95% CI 1.24, 28.83). Reductions were observed in mean daily β-agonist use (1.0 puff/day [95% CI -1.61, -0.26]), mean daytime symptom scores, and nocturnal awakenings over the 101/3 day treatment period. There were no important differences between the groups receiving and those not receiving inhaled corticosteroids. Montelukast was well tolerated with no serious clinical adverse events reported. Conclusions: In this study Montelukast, 200 mg, administered three times daily for 101/3 days, compared with placebo, was generally well tolerated and resulted in significant improvement in chronic asthma, irrespective of the presence of inhaled corticosteroids.

AB - Background: Cysteinyl leukotrienes mediate signs and symptoms of asthma. In a double-blind, placebo-controlled, crossover study, a new potent and specific cysteinyl leukotriene (LTD4) receptor antagonist, montelukast (MK-0476), was evaluated for tolerability and clinical efficacy in patients with chronic asthma (receiving and not receiving inhaled corticosteroids). Methods: Twenty-nine nonsmoking patients with asthma (15 treated concomitantly with inhaled corticosteroids) with FEV1 percent predicted values between 50% to 80% received MK-0476, 200 mg, or placebo three times daily for 101/3 days (31 doses) in a random, crossover manner, after a 2-week, open, baseline period. Comparisons in FEV1 (mean percent change from baseline after the first and last dose), mean daily daytime asthma and nocturnal awakening scores, and mean daily β-agonist use were made between treatment periods. Results: Montelukast, compared with placebo, caused improvements in FEV1 (mean percentage point difference of the percentage change from baseline) 3 and 4 hours after dosing on day 1 (hour 3, 9.0%; 95% confidence interval [CI] 0.53, 18.72; hour four, 10.9%; 95% CI - 0.25, 20.20) and day 11 (hour 3, 14.0%; 95% CI 0.76, 31.43; hour 4, 13.4%; 95% CI 1.24, 28.83). Reductions were observed in mean daily β-agonist use (1.0 puff/day [95% CI -1.61, -0.26]), mean daytime symptom scores, and nocturnal awakenings over the 101/3 day treatment period. There were no important differences between the groups receiving and those not receiving inhaled corticosteroids. Montelukast was well tolerated with no serious clinical adverse events reported. Conclusions: In this study Montelukast, 200 mg, administered three times daily for 101/3 days, compared with placebo, was generally well tolerated and resulted in significant improvement in chronic asthma, irrespective of the presence of inhaled corticosteroids.

UR - http://www.scopus.com/inward/record.url?scp=0029970797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029970797&partnerID=8YFLogxK

M3 - Article

VL - 98

SP - 528

EP - 534

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -